Released on: September 5, 2007, 6:52 am

Press Release Author: Ballou PR

Industry: Biotech

Press Release Summary: Cisbio and Lumiphore Announce Partnership for New Product and
Technology Development Incorporating Lumi4T Compounds

Press Release Body: Bagnols-sur-Cèze, France and Redwood City, CA, U.S.A. -
September 5, 2007 - Cisbio, a global developer of HTRF® (Homogeneous Time-Resolved
Fluorescence) technology and services used in assay development and drug screening,
and Lumiphore, Inc., an early-stage biotechnology company developing proprietary
lanthanide technology for use in high-value applications, announced that they have
signed an exclusive agreement for the incorporation of Lumiphore's Lumi4T complexes
in Cisbio assays.

Under the agreement, Cisbio holds the exclusive rights to apply Lumi4T technology to
current and future research and development initiatives in TR-FRET-based
(Time-Resolved Fluorescence Resonance Energy Transfer) assays for drug discovery.
Lumi4T compounds bring excellent photophysical properties, increased sensitivity and
stability to TR-FRET assays for high-throughput screening (HTS) applications and the
growing homogeneous assay market. The incorporation of Lumi4T compounds to Cisbio's
proprietary HTRF® technology has the potential to enable the development of a second
generation of assay platforms used in HTS, particularly in the fields of GPCR
(G-Protein Coupled Receptors) and kinase screening.

\"This agreement represents a major step in our quest for highly performing TR-FRET
assays,\" said François Degorce, head of HTRF® marketing and business development,
Cisbio. \"We strongly believe that Lumi4T compounds will enable us to widen our HTRF®
product portfolio and strengthen our leading position in this field.\"

HTRF® is a highly sensitive, robust technology for the detection of molecular
interactions of proteins in vitro and is widely used for primary and secondary
screening phases of drug development. HTRF® combines standard FRET technology with
time-resolved measurement of fluorescence. During the FRET process, HTRF®
fluorophores emit long-lived fluorescence which can be discriminated from
short-lived background fluorescence, boosting detection of these homogeneous assays.


Lumi4T complexes are a new class of fluorescent lanthanide detection reagents based
on lanthanide technology patented by Professor Kenneth N. Raymond, chairman and
president of Lumiphore, and coworkers at the University of California, Berkeley.
Lanthanides are used as reagents by researchers due to their strong luminescent
properties, and these patents relate to a shell surrounding the lanthanide molecule
which enables them to be used as extremely efficient FRET donors. These complexes
have long emission lifetimes and offer a number of major advantages over existing
fluorophores used for detection, including higher signal-to-noise ratio and
stability.

"Cisbio has an extensive HTRF® product line and expertise in drug discovery
research, and our agreement with them validates the capabilities of Lumiphore's
technology," said Professor Raymond. "We look forward with excitement and enthusiasm
to a productive partnership."

Combining the two technologies will allow for the development of new HTRF®
applications and increased possibilities for HTS implementation of Cisbio's assays.

###



About Cisbio
Cisbio is a global developer of products and technologies used in nuclear medicine,
in vitro diagnostics and assay development for drug screening procedures. The
company pioneered the field of homogenous fluorescence methodologies via its
proprietary technology, HTRF®, a highly sensitive, robust technology for the
detection of molecular interactions and widely used by the pharmaceutical industry
for the high throughput screening stage of drug development. In addition, Cisbio
produces a selection of biological reagents and methods used by pharmaceutical and
biotechnology companies, as well as contract research organizations (CROs). For more
information about Cisbio and HTRF®, log onto www.cisbio.com and www.htrf.com.

HTRF® is a registered trademark of Cisbio.


About Lumiphore
Lumiphore is an early stage biotechnology company developing proprietary lanthanide
technology for use in high-value applications and commercializing the technology by
entering into market-specific alliances with corporate partners. Lumiphore has
exclusive licenses to the basic science developed at the University of California,
Berkeley, laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide
chemistry. Lanthanide reporters provide increased sensitivity for fluorescent
reagents in biology, since they make possible time-resolved detection, which results
in vastly improved signal-to-noise. For more information about Lumiphore, log onto
www.lumiphore.com.

Lumi4T is a trademark of Lumiphore, Inc.


Web Site: http://

Contact Details: Ballou PR
Paris, France
+33-1 42 22 24 10
christina@balloupr.com